Axsome Therapeutics AXSM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Axsome Therapeutics (AXSM) Business Model and Operations Summary
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Key Insights
Axsome Therapeutics (AXSM) Core Market Data and Business Metrics
Latest Closing Price
$109.75Market Cap
$5.35 BillionPrice-Earnings Ratio
-18.32Total Outstanding Shares
48.77 Million SharesTotal Employees
589Dividend
No dividendIPO Date
November 19, 2015SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
One World Trade Center, 22nd Floor, New York, NY, 10007
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 610,071 Shares | 8.04 | 3/14/2025 | 4,905,057 Shares |
| 1,021,353 Shares | 5.59 | 2/28/2025 | 5,710,793 Shares |
| 1,288,585 Shares | 4.55 | 2/14/2025 | 5,867,051 Shares |
| 959,751 Shares | 5.84 | 1/31/2025 | 5,607,008 Shares |
| 998,323 Shares | 5.76 | 1/15/2025 | 5,752,862 Shares |
| 878,436 Shares | 7.54 | 12/31/2024 | 6,619,135 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-270,000 |
| Net Cash Flow From Financing Activities, Continuing | $57.84 Million |
| Net Cash Flow From Operating Activities, Continuing | $-128.41 Million |
| Net Cash Flow | $-70.84 Million |
| Net Cash Flow From Financing Activities | $57.84 Million |
| Net Cash Flow, Continuing | $-70.84 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-5.99 |
| Interest Expense, Operating | $-21.58 Million |
| Basic Earnings Per Share | $-5.99 |
| Benefits Costs and Expenses | $672.82 Million |
| Income/Loss From Continuing Operations After Tax | $-287.22 Million |
| Revenues | $385.69 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-287.22 Million |
| Comprehensive Income/Loss | $-287.22 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $72.00 Million |
| Assets | $568.50 Million |
| Equity Attributable To Parent | $57.02 Million |
| Fixed Assets | $584,000 |
| Equity | $57.02 Million |
| Other Current Assets | $469.33 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||